Prevalence and Predictors of Poor Sleep Quality in Inflammatory Bowel Disease: A Cross-Sectional Cohort Study (ACG 2026) - Aug 29, 2026 - Abstract #P1198; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "AZA, azathioprine; 6-MP, 6-mercaptopurine; CZP, certolizumab pegol; HBI, Harvey-Bradshaw Index; IFX, infliximab; PSQI, Pittsburgh Sleep Quality Index; RZB, risankizumab; TNF, tumour necrosis factor; TOFA, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VDZ, vedolizumab. A total of 215 patients (71.2% Crohnâs, 42.3% female, median age 30) completed the PSQI. Of these patients, 201 (93.5%) had classifiable IBD activity (69 Active, 132 Quiescent) and were included in the analysis. Poor sleep was noted in 62.3%, depression (HADS-D ⥠8) in 30.7% and anxiety (HADS-A ⥠8) in 35.2% of the entire cohort."
CNS Disorders • Crohn's disease • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mood Disorders • Sleep Disorder
|
|
Naif Alrossais MD 1; Samhar Alouch 2; Abdul Razzak Chalab Cham MBBS 2; Mohamed Naim Khalil MBBS 2; Haneen Abu Raida MBBS 2; Abdulelah Almutairdi MD 1; Mashary Attamimi MD 1; Muhannad Hawari MD 1; Badr Al-Bawardy MBBS 1
|